# A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

> **NCT03251482** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 308 (actual)

## Conditions studied

- VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery

## Interventions

- **DRUG:** JNJ-64179375 0.3 mg/kg
- **DRUG:** JNJ-64179375 0.6 mg/kg
- **DRUG:** JNJ-64179375 1.2 mg/kg
- **DRUG:** JNJ-64179375 (Dose to be Determined)
- **DRUG:** JNJ-64179375 A mg/kg
- **DRUG:** JNJ-64179375 B mg/kg
- **DRUG:** JNJ-64179375 C mg/kg
- **DRUG:** JNJ-64179375 D mg/kg
- **DRUG:** Placebo JNJ-64179375
- **DRUG:** Apixaban placebo
- **DRUG:** Apixaban 2.5 mg

## Key facts

- **NCT ID:** NCT03251482
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-13
- **Primary completion:** 2018-11-05
- **Final completion:** 2018-11-05
- **Target enrollment:** 308 (ACTUAL)
- **Last updated:** 2019-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03251482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03251482, "A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03251482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*